Identifying treatment options for rare breast tumors through genetic analysis
Official title: Defining Actionable Opportunities in Malignant Phyllodes via Genomic Profiling
Funded at Duke University · NIH-11062921 · Data updated 2026-11-12
This study is looking at the genetic features of rare and aggressive breast tumors called malignant phyllodes tumors to find new treatment options that could help patients who are at high risk of their cancer coming back or spreading.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 5, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,489,181 |
| NIH project number | 1U01FD007909-01A1 |
| Project ID | NIH-11062921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with malignant phyllodes tumors or borderline phyllodes tumors.
✕Less likely to help
Patients with benign phyllodes tumors or other types of breast cancer may not benefit from this research.
What this research studies
This research focuses on malignant phyllodes tumors (MPT), which are rare and aggressive forms of breast cancer. The study aims to analyze the genetic makeup of these tumors to identify potential treatment options that could improve patient outcomes. By understanding the genomic alterations present in MPT, researchers hope to find existing FDA-approved therapies that could be effective for patients at high risk of recurrence or metastasis. This approach seeks to provide actionable insights that could lead to better management of this challenging condition.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with malignant phyllodes tumors, potentially improving survival rates.
How similar studies have gone: While research on malignant phyllodes tumors is limited, similar genomic profiling approaches have shown promise in identifying treatment options for other rare cancers.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Rosenberger, Laura Horst — Duke University
- Study coordinator: Rosenberger, Laura Horst
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.